Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Earnings Data
Report Date
Apr 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.99Last Year’s EPS
-0.44Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive outlook supported by transformational 2025 results — nearly $3B product sales (81% YoY), robust Q4 performance, GAAP profitability, a deep and advancing pipeline (three Phase 3 starts) and ambitious 2030 goals — while responsibly acknowledging near-term headwinds including margin pressure from royalties, expected mid-single-digit net price declines, Q1 phasing impacts (notably a ~ $25M international adjustment), and higher planned R&D/SG&A investments. Management provided clear 2026 guidance (product revenue $4.9B–$5.3B, TTR $4.4B–$4.7B) and articulated how platform, pipeline, and manufacturing scale underpin sustained growth. Overall, the positives (strong growth, profitability, pipeline depth, funded strategy) materially outweigh the manageable near-term challenges.Company Guidance
Record Full-Year Product Revenue and Strong Growth
Total global net product revenues for 2025 were nearly $3.0 billion, representing 81% growth versus 2024, driven primarily by the Amvuttra ATTR cardiomyopathy launch.
Exceptional Q4 Performance
Q4 2025 combined net product revenues were $995 million, up 121% year-over-year and 17% sequentially; TTR franchise Q4 net revenues were $858 million (151% YoY, 18% QoQ).
Achieved GAAP and Non-GAAP Profitability
Alnylam achieved both GAAP and non-GAAP net income profitability in Q4 and for full year 2025; full-year non-GAAP operating income was $850 million, a $755 million increase versus prior year.
Robust Commercial Momentum in TTR and Rare Disease
The TTR franchise is the primary growth engine with strong U.S. Amvuttra uptake (approaching parity with tafamidis in new starts early post-launch); rare disease franchise delivered $136 million in Q4 (up 26% YoY) and GIVLAARI plus OXLUMO became a $500 million franchise in 2025.
Ambitious and Funded Long-Term Strategy (Alnylam 2030)
Management announced 2030 goals including >25% revenue CAGR through 2030 and a 30% non-GAAP operating margin across the period, plans to invest ~30% of revenues in non-GAAP R&D, and targets to expand to >40 clinical programs and delivery to 10 tissue types by 2030.
Pipeline and Clinical Progress
Initiated three Phase 3 trials in 2025 (ZENITH ~11,000 patients for zalesiran; TRITON-CM ~1,200 and TRITON-PN ~125 for nuceresiran) and expanded the clinical pipeline to over 25 active programs with four new Alnylam-led CTAs in 2025.
Platform & Manufacturing Innovation
Launched Cyrillis, an enzymatic ligation-based RNAi manufacturing platform intended to expand capacity and reduce cost of goods, supporting scale-up of RNAi therapeutics.
Solid Financial Position and Upside from Partnerships
Ended 2025 with $2.9 billion in cash, cash equivalents and marketable securities (up $200 million year-over-year); collaboration revenue grew to $553 million (+8% YoY) and royalty revenue increased to $104 million (+90% YoY), providing diversification of revenue streams.
GB:0HD2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0HD2 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $321.15 | $308.85 | -3.83% |
Oct 30, 2025 | $479.55 | $446.58 | -6.87% |
Jul 31, 2025 | $344.49 | $392.07 | +13.81% |
May 01, 2025 | $260.21 | $264.30 | +1.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alnylam Pharmaceuticals (GB:0HD2) report earnings?
Alnylam Pharmaceuticals (GB:0HD2) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
What is Alnylam Pharmaceuticals (GB:0HD2) earnings time?
Alnylam Pharmaceuticals (GB:0HD2) earnings time is at Apr 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Alnylam Pharmaceuticals stock?
The P/E ratio of Alnylam Pharma is N/A.
What is GB:0HD2 EPS forecast?
GB:0HD2 EPS forecast for the fiscal quarter 2026 (Q1) is 0.99.